1,5-Didesoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol
MKC-542 · BAY-o-1248 · Emiglitate · 1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol · 1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol USP/EP/BP · 4-[2-[(2R,3R,4R,5S)-3,4,5-Trihydroxy-2-(hydroxymethyl)piperidino]ethoxy]benzoic acid ethyl ester · Benzoic acid, 4-[2-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]ethoxy]-, ethyl ester
![Molekülstruktur von 1,5-Didesoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol](/img/chemical/72004.png)
Identifikatoren & physikalische Daten
| CAS No. | 80879-63-6 |
|---|---|
| Summenformel | C17H25NO7 |
| Durchschnittliche Molmasse | 355,4 g/mol |
| Monoisotopische Masse | 355,16310214 g/mol |
| SMILES | CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1 |
| InChIKey | NWWORXYTJRPSMC-QKPAOTATSA-N |
| PubChem CID | 72004 |
| ChEMBL | CHEMBL2106304 |
| ChEBI | CHEBI:230574 |
| EC No. | 279-613-2 |
| DTXSID | DTXSID2048799 |
| Lokaler Name | 1,5-Didesoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol |
Chemische & physikalische Eigenschaften
| XLogP | 0 |
|---|---|
| Polarare Oberfläche (TPSA) | 120 |
| H-Brücken-Donoren | 4 |
| H-Brücken-Akzeptoren | 8 |
| Frei drehbare Bindungen | 8 |
| Schwere Atome | 25 |
| Formalladung | 0 |
| Komplexität | 414 |
| Arzneimittel | Pharmaceuticals -> Antibiotics |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Siedepunkt | 580.2±50.0 °C(Predicted) |
| Dichte | 1.328±0.06 g/cm3(Predicted) |
| Lagerbedingungen | Store at -20°C |
| Löslichkeit | Soluble in DMSO |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | 13.68±0.70(Predicted) |
| Farbe | White to off-white |
Anwendungen & Verwendung
Beschreibung
Emiglitate (BAY O 1248), another deoxynojirimycin analogue is characterized by at least five-fold higher inhibitory potency than acarbose and additionally shows a long-lasting inhibitory effect. In animal studies emiglitate was still active up to 17 h after a single oral administration due to its pharmacokinetic behavior (formation of an active metabolite). Both miglitol and emiglitate differ in their pharmacokinetic behavior from acarbose, which is poorly absorbed (1 – 2 %). The deoxynojirimycin derivatives are structurally related to monosaccharides and will be absorbed in the jejunum.